One case series of patients with refractory MAS+/− lung disease treated with moderate dosing of the chemotherapy agent etoposide (a mainstay of treatment in primary haemophagocytic lymphohistiocytosis (HLH) [36]) included five patients with Still’s [37]. Here, MAS1 is linked to hemophagocytic syndrome.